Polynucleotides and Polypeptide Sequences Involved in Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/CA2012/000296, filed Mar 28, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,216,582 | Polynucleotides and Polypeptide Sequences Involved in Cancer In force · High confidence UsedRemaining | ADC Therapeutics S.A. | In force | High confidence | ||
| US 8,937,163 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · High confidence | ADC Therapeutics S.A. | In force | High confidence | ||
| US 9,393,302 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · Medium confidence | ADC Therapeutics S.A. | In force | Medium confidence | ||
| US 10,597,450 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · Medium confidence | ADC Therapeutics S.A. | In force | Medium confidence | ||
| US 8,580,257 | Antibodies That Specifically Block the Biological Activity of Kidney Associated Antigen 1 (KAAG1) Lapsed Nov 12, 2025 on the fee record High confidence | ADC Therapeutics S.A. | Lapsed Nov 12, 2025 on the fee record | High confidence | ||
| US 9,828,426 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof Lapsed Nov 28, 2025 on the fee record High confidence | ADC Therapeutics S.A. | Lapsed Nov 28, 2025 on the fee record | High confidence | ||
| US 9,855,291 | Anti-Kidney Associated Antigen 1 (KAAG1) Antibodies Lapsed Jan 2, 2026 on the fee record High confidence | ADC Therapeutics S.A. | Lapsed Jan 2, 2026 on the fee record | High confidence | ||
| Application 13/490,857 | Polynucleotides and Polypeptide Sequences Involved in Cancer Abandoned Abandoned May 20, 2015 | ADC Therapeutics S.A. | Abandoned | Abandoned May 20, 2015 | ||
| Application 14/690,562 | Polynucleotides and Polypeptide Sequences Involved in Cancer Abandoned Abandoned Jan 29, 2018 | ADC Therapeutics S.A. | Abandoned | Abandoned Jan 29, 2018 | ||
| Application 15/833,753 | Antibodies That Specifically Block the Biological Activity of a Tumor Antigen Abandoned Abandoned Sep 6, 2022 | ADC Therapeutics S.A. | Abandoned | Abandoned Sep 6, 2022 | ||
| 2 more records in this group · Pro | ||||||
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12, including 3 expired.
4 of these are in force and held by ADC Therapeutics S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.